IMP3 expression is correlated with histologic grade of lung adenocarcinoma

Human Pathology

Volumn 41, Issue 4, 2010, Pages 477-484

  Findeis Hosey, Jennifer J ^a   Yang, Qi ^a   Spaulding, Betsy O ^b   Wang, Hanlin L ^c   Xu, Haodong ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b AGILENT TECHNOLOGIES   (United States)

^c Cedars Sinai Medical Center   (United States)

Author keywords

AAH; Adenocarcinoma; Atypical adenomatous hyperplasia; BAC; Bronchioloalveolar carcinoma; IMP3; KOC; Lung; RNA binding protein

Indexed keywords

INSULIN LIKE GROWTH FACTOR 2 MRNA BINDING PROTEIN 3; ONCOFETAL ANTIGEN; UNCLASSIFIED DRUG;

ADENOMA; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CELL DIFFERENTIATION; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; MAJOR CLINICAL STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; LUNG; LUNG NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM STAGING; PRECANCEROUS CONDITIONS; RNA-BINDING PROTEINS;

EID: 77649336678     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2009.10.004     Document Type: Article

References (27)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Devesa S.S., Bray F., Vizcaino A.P., et al. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 117 (2005) 294-299
3. Sun Z., Aubry M.C., Deschamps C., et al. Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 hospital- and 712 population-based cases. J Thorac Cardiovasc Surg 131 (2006) 1014-1020
4. Sica G., Travis W.D., and Moreira A. Strong correlation between solid and micropapillary subtypes of lung adenocarcinoma (AD) in primary and metastatic sites (Abstract). Mod Pathol 22 Suppl I (2009) 361A-362A
5. Travis W.D., Colby T., Corrin B., et al. Tumors of the lung. In: Kleihues P., and Sobin L.H. (Eds). WHO classification of tumors. Pathology and genetics of tumors of the lung, pleura, thymus and heart (2004), IARC press, Lyon, France 38
6. Zell J.A., Ou S.H., Ziogas A., et al. Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors. J Clin Oncol 23 (2005) 8396-8405
7. Dacic S. Pulmonary preneoplasia. Arch Pathol Lab Med 132 (2008) 1073-1078
8. Sartori G., Cavazza A., Bertolini F., et al. A subset of lung adenocarcinomas and atypical adenomatous hyperplasia-associated foci are genotypically related: an EGFR, HER2, and K-ras mutational analysis. Am J Clin Pathol 129 (2008) 202-210
9. Nielsen J., Christiansen J., Lykke-Andersen J., et al. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 19 (1999) 1262-1270
10. Wang T., Fan L., Watanabe Y., et al. L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. Br J Cancer 88 (2003) 887-894
11. Liao B., Hu Y., Herrick D.J., et al. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem 280 (2005) 18517-18524
12. Yantiss R.K., Woda B.A., Fanger G.R., et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol 29 (2005) 188-195
13. Mueller-Pillasch F., Lacher U., Wallrapp C., et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 14 (1997) 2729-2733
14. Jiang Z., Chu P.G., Woda B.A., et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 7 (2006) 556-564
15. Xu H., Bourne P.A., Spaulding B.O., et al. High-grade neuroendocrine carcinomas of the lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not. Hum Pathol 38 (2007) 555-563
16. Simon R., Bourne P.A., Yang Q., et al. Extrapulmonary small cell carcinomas express K homology domain containing protein overexpressed in cancer, but carcinoid tumors do not. Hum Pathol 38 (2007) 1178-1183
17. Li C., Zota V., Woda B.A., et al. Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations. Mod Pathol 20 (2007) 1263-1268
18. Pryor J.G., Bourne P.A., Yang Q., et al. IMP-3 is a novel progression marker in malignant melanoma. Mod Pathol 21 (2008) 431-437
19. Hanley K.Z., Facik M.S., Bourne P.A., et al. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions. Cancer 114 (2008) 49-56
20. Vikesaa J., Hansen T.V., Jonson L., et al. RNA-binding IMPs promote cell adhesion and invadopodia formation. Embo J 25 (2006) 1456-1468
21. Istvanic S., Fanger G., Fraire A., et al. Spectrum of KOC (K homology domain containing protein over-expressed in cancer) immunostaining among carcinomas of different sites. Mod Pathol 18 (2005) 298A-299A
22. Bellezza G., Cavaliere A., and Sidoni A. IMP3 expression in non-small cell lung cancer. Hum Pathol 40 (2009) 1205-1206
23. In: Edge S.B., Byrd D.R., Compton C.C., et al. (Eds). AJCC cancer staging manual 7th edition (2010), Springer, Chicago, IL 253-270
24. Chao W., and D'Amore P.A. IGF2: epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev 19 (2008) 111-120
25. Foulstone E., Prince S., Zaccheo O., et al. Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol 205 (2005) 145-153
26. Quinn K.A., Treston A.M., Unsworth E.J., et al. Insulin-like growth factor expression in human cancer cell lines. J Biol Chem 271 (1996) 11477-11483
27. Takanami I., Imamuma T., Hashizume T., et al. Insulin-like growth factor-II as a prognostic factor in pulmonary adenocarcinoma. J Surg Oncol 61 (1996) 205-208